预约演示
更新于：2025-04-18
Fenofibrate
非诺贝特
更新于：2025-04-18
概要
基本信息
简介非诺贝特是一种小分子药物，具有靶向过氧化物酶体增殖物激活受体α (PPARα) 作为激动剂的独特能力。自 1974 年 11 月法国著名制药企业 Fournier Pharma SA 首次批准该药物以来，该药物已广泛用于治疗血液中的高胆固醇和甘油三酯水平。非诺贝特通过调用 PPARα 发挥作用，PPARα 熟练地调节脂质代谢，最终大幅减少肝脏内胆固醇和甘油三酯的产生。这种强效药物有多种剂型，从胶囊到片剂，通常口服。尽管非诺贝特具有悠久的历史，但它仍然是一种非常有效的治疗选择，可以满足全世界患有血脂异常和相关疾病的患者的需求，因此继续被医疗保健提供者开具处方。 |
药物类型 小分子化药 |
别名 2-(4-(4-Chlorobenzoyl)phenoxy)-2-methylpropanoic acid 1-methylethyl ester、Fenofibrate (JAN/USP/INN)、Finofibrate + [28] |
靶点 |
作用方式 激动剂 |
作用机制 PPARα激动剂(过氧化物酶体增长因子活化受体α激动剂) |
非在研适应症 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C20H21ClO4 |
InChIKeyYMTINGFKWWXKFG-UHFFFAOYSA-N |
CAS号49562-28-9 |
关联
241
项与 非诺贝特 相关的临床试验NCT06905054
Peroxisome Proliferator-Activated Receptor Agonists to Prevent Primary Sclerosing Cholangitis Recurrence After Liver Transplantation
ChiCTR2500100214
Clinical Study on Fenofibrate Improving Neuroinflammation and Cognitive Decline After TBI
NCT06858332
Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia
100 项与 非诺贝特 相关的临床结果
登录后查看更多信息
100 项与 非诺贝特 相关的转化医学
登录后查看更多信息
100 项与 非诺贝特 相关的专利（医药）
登录后查看更多信息
6,677
项与 非诺贝特 相关的文献（医药）2025-06-01EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
Self-dispersible eutectic mixtures with fenofibrate and ibuprofen: Processability and API particle size
Article
作者: Schlosser, Peter ; Bunjes, Heike
In order to increase the dissolution rate of poorly water-soluble drugs, the preparation of eutectics is a practical way to minimize the drug particle size without the need of grinding and handling of poorly flowing powders. The use of solid self-dispersible excipients as a component of the eutectic may further enhance the drug dissolution rate. In the current study, phase diagrams of eutectic mixtures of polyethylene glycol stearates and polyethylene glycol stearyl ethers differing in their polyethylene glycol chain lengths and two model drugs were established. Their processability and disintegration properties were investigated. Moreover, the resulting drug particle sizes in the eutectics were determined. The eutectic concentration and temperature of fusion of the eutectics increased with the melting temperature of the respective excipient. The eutectics with the self-dispersing excipients disintegrated faster than more conventional eutectics containing polyethylene glycols that were prepared for comparison. The drug particle sizes were smaller for mixtures with higher recrystallization tendency and with drug concentrations close to the eutectic concentration.
2025-06-01EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
Co-milling of glass forming ability class III drugs: Comparing the impact of low and high glass transition temperatures
Article
作者: Beránek, Josef ; O'Dwyer, Patrick J ; Pätzmann, Nicolas ; Griffin, Brendan T ; Kuentz, Martin
With an increasing focus on sustainable technologies in the pharmaceutical industry, milling provides a solvent-free approach to improve drug dissolution. Milling of drugs with an excipient offers additional opportunities to achieve supersaturation kinetics. Therefore, this work aims to present insights of co-milling fenofibrate and apremilast, two good glass formers with low and high glass transition temperatures (Tgs) respectively. Drugs were co-milled with croscarmellose sodium for various process durations followed by thermal analysis, investigation of crystallinity, surface area and dissolution. The dissolution enhancement of the low-Tg glass former fenofibrate highly correlated with the process-induced increase in surface area of co-milled systems (R2 = 0.96). In contrast, the high-Tg glass former apremilast lost its crystalline order gradually after ≥ 10 min of co-milling, and favourable supersaturation kinetics during biorelevant dissolution testing were observed. Interestingly, the melting point of co-milled apremilast decreased and linearly correlated with the highest measured drug concentration (cmax) during in vitro dissolution (onset temperature R2 = 0.98; peak temperature R2 = 0.96). The melting point depression remained stable after 90 days for apremilast, whereas fenofibrate co-milled for 20 min or more showed an increase in melting point upon storage. This study demonstrated that co-milling with croscarmellose sodium is ideally suited to good glass formers with a high Tg. The melting point depression is thereby proposed as an easily accessible critical quality attribute to estimate likely dissolution performance of drugs in dry co-milled formulations.
2025-06-01Toxicology reports
Fenofibrate ameliorated atorvastatin and piperine-induced ROS mediated reproductive toxicity in male Wistar rats
Article
作者: Biswas, Maharaj ; Sarkar, Sweata ; Ghosh, Sanjib
Atorvastatin and fenofibrate are well-known lipid-lowering drugs. Atorvastatin acts by reducing the production of cholesterol through the inhibition of the 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMG Co-A reductase) enzyme, whereas fenofibrate is a PPAR-α agonist. Piperine is an alkaloid mostly found in black pepper fruits. The present study was planned to evaluate the activities of atorvastatin, fenofibrate, and piperine on the male reproductive system. A total of 35 male Wistar rats were obtained for the experiment. Rats were randomly divided into 7 groups, each group with 5 rats. The experiment was run for 28 days. Group I rat got normal meals for 28 days; Group II received atorvastatin (08 mg/kg/day); Group III received piperine (10 mg/kg/day); and Group IV received fenofibrate (20 mg/kg/day). Group V received atorvastatin (8 mg/kg/day) and piperine (10 mg/kg/day); Group VI received piperine (10 mg/kg/day) and fenofibrate (20 mg/kg/day). VII received fenofibrate (20 mg/kg bw/day) and atorvastatin (8 mg/kg/day). After sacrifice, serum and testicular cholesterol and testosterone levels assessed by ELISA, ROS generation analysed by using flow cytometry, MDA, SOD, and catalase were measured. Histological, sperm-parameter analysis, and spermatogenic evaluations were also done. Activities of atorvastatin and piperine revealed reproductive toxicity upon treatment. Fenofibrate treatment, along with atorvastatin and piperine, showed protective effects. In conclusion, atorvastatin and piperine affected reproductive potential, whereas fenofibrate might have protective efficacy against atorvastatin and piperine-induced reproductive toxicity.
100 项与 非诺贝特 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 家族性混合型高脂血症 | 美国 | 2007-08-10 | |
| 脂蛋白脂肪酶循环抑制剂所致家族性乳糜微粒血症 | 美国 | 2001-09-04 | |
| 先天性畸形 | 美国 | 2001-09-04 | |
| 冠状动脉疾病 | 美国 | 2001-09-04 | |
| 糖尿病 | 美国 | 2001-09-04 | |
| 血脂障碍 | 美国 | 2001-09-04 | |
| 高脂血症 | 美国 | 2001-09-04 | |
| I型高脂蛋白血症 | 美国 | 2001-09-04 | |
| IV型高脂蛋白血症 | 美国 | 2001-09-04 | |
| 高脂蛋白血症 | 美国 | 2001-09-04 | |
| 甲状腺功能减退症 | 美国 | 2001-09-04 | |
| 胰腺炎 | 美国 | 2001-09-04 | |
| 原发性高胆固醇血症 | 美国 | 2001-09-04 | |
| 高胆固醇血症 | 法国 | 1974-11-04 | |
| 高甘油三酯血症 | 法国 | 1974-11-04 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 1型糖尿病 | 临床3期 | 澳大利亚 | 2016-11-03 | |
| 1型糖尿病 | 临床3期 | 中国香港 | 2016-11-03 | |
| 1型糖尿病 | 临床3期 | 新西兰 | 2016-11-03 | |
| 1型糖尿病 | 临床3期 | 英国 | 2016-11-03 | |
| 糖尿病肾病 | 临床3期 | 澳大利亚 | 2016-11-03 | |
| 糖尿病肾病 | 临床3期 | 中国香港 | 2016-11-03 | |
| 糖尿病肾病 | 临床3期 | 新西兰 | 2016-11-03 | |
| 糖尿病肾病 | 临床3期 | 英国 | 2016-11-03 | |
| 糖尿病性视网膜病变 | 临床3期 | 澳大利亚 | 2016-11-03 | |
| 糖尿病性视网膜病变 | 临床3期 | 中国香港 | 2016-11-03 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 1,151 | 鏇鏇範壓鬱遞積鏇觸鬱(選餘顧構顧鏇窪築襯艱) = 積襯鏇襯艱鏇願齋廠選 構製齋齋觸構鏇齋獵糧 (壓襯構鏇壓鬱淵醖簾憲 ) 更多 | 积极 | 2024-06-21 | |||
Placebo | 鏇鏇範壓鬱遞積鏇觸鬱(選餘顧構顧鏇窪築襯艱) = 繭範觸觸壓蓋餘顧鑰範 構製齋齋觸構鏇齋獵糧 (壓襯構鏇壓鬱淵醖簾憲 ) 更多 | ||||||
N/A | 2型糖尿病 Haptoglobin (Hp) | 8,047 | 窪憲築廠衊膚構範膚製(淵遞鑰遞壓淵廠觸製膚) = During run-in fenofibrate reduced Hp level by 20.7%, p<0.001 鬱憲遞鑰壓憲顧築壓蓋 (繭壓醖鑰窪糧艱齋構襯 ) | 积极 | 2024-06-14 | ||
临床3期 | 65 | 壓淵築製憲齋觸願憲壓(窪遞餘網簾鹹遞積遞壓) = 憲鏇醖鏇遞願蓋顧簾衊 鹽夢願積網憲鏇窪鹹積 (顧構衊製願範選鏇獵鬱, 145.3) | 积极 | 2024-06-14 | |||
壓淵築製憲齋觸願憲壓(窪遞餘網簾鹹遞積遞壓) = 網獵淵積膚鏇衊製鏇簾 鹽夢願積網憲鏇窪鹹積 (顧構衊製願範選鏇獵鬱, 75.7) | |||||||
临床2期 | 10 | (Active) | 糧構獵獵窪範蓋選壓簾(齋窪獵鑰餘顧艱糧壓襯) = 鏇願鏇網遞廠構醖壓壓 窪蓋餘鏇襯憲範窪壓顧 (窪齋鏇夢鬱蓋鹽鬱觸選, 0.9017336) 更多 | - | 2023-09-28 | ||
Placebo (Placebo) | 糧構獵獵窪範蓋選壓簾(齋窪獵鑰餘顧艱糧壓襯) = 簾簾簾齋製醖築鏇壓鹽 窪蓋餘鏇襯憲範窪壓顧 更多 | ||||||
临床3期 | 癫痫 辅助 | 340 | 憲淵獵餘窪簾顧網顧廠(繭鏇衊鏇鹹觸範選廠願) = notably reduced in fenofibrate group compared to placebo group 築衊夢網醖鹽構鹹餘膚 (餘築簾網簾鑰簾遞簾鬱 ) 更多 | 积极 | 2023-09-04 | ||
Placebo | |||||||
N/A | 117 | UDCA-only | 築鹹壓壓衊糧鑰糧選鹹(醖鹹廠構廠顧鹽糧繭顧) = 構鑰製網願鹽構淵齋窪 觸壓襯醖繭選製廠醖築 (襯範膚繭廠繭廠繭構艱, 51.9 ~ 76.8) | 积极 | 2023-03-09 | ||
UDCA-Fenofibrate | 築鹹壓壓衊糧鑰糧選鹹(醖鹹廠構廠顧鹽糧繭顧) = 鹹網觸膚憲蓋顧鹹願膚 觸壓襯醖繭選製廠醖築 (襯範膚繭廠繭廠繭構艱, 69.9 ~ 92.9) | ||||||
临床3期 | 551 | (K-877) | 壓襯遞獵選網選襯餘範(鏇醖鏇鹽餘網繭網衊醖) = 簾糧夢膚壓鹽淵積鑰窪 觸衊衊窪淵顧觸網衊願 (窪遞憲願窪廠顧鏇鏇夢, 憲鬱築鹽憲網鑰壓築夢 ~ 遞憲遞襯糧壓餘壓膚繭) 更多 | - | 2022-11-30 | ||
Placebo+K-877 (Placebo) | 壓襯遞獵選網選襯餘範(鏇醖鏇鹽餘網繭網衊醖) = 選齋觸鬱網醖餘鹹夢築 觸衊衊窪淵顧觸網衊願 (窪遞憲願窪廠顧鏇鏇夢, 衊獵壓艱膚鏇襯積鹽襯 ~ 觸壓鏇築簾願顧衊齋獵) 更多 | ||||||
N/A | 692 | Statin plus fenofibrate | 鑰膚襯齋繭壓獵選鏇襯(積廠壓築鹽獵醖齋齋鹽): HR = 0.89 (95% CI, 0.81 ~ 0.98), P-Value = 0.022 更多 | 积极 | 2022-09-21 | ||
Statin-only | |||||||
N/A | 384 | 顧顧糧鑰鏇積憲築糧膚(鏇膚遞鏇憲鏇獵廠廠鏇) = 鏇齋膚製選夢廠壓積積 選淵簾積窪範襯糧選衊 (窪選襯範積繭簾鏇遞積 ) 更多 | 不佳 | 2022-09-04 | |||
顧顧糧鑰鏇積憲築糧膚(鏇膚遞鏇憲鏇獵廠廠鏇) = 夢願鏇遞鹹願壓選糧糧 選淵簾積窪範襯糧選衊 (窪選襯範積繭簾鏇遞積 ) 更多 | |||||||
N/A | 75 | 遞簾鹽獵遞廠膚製鹹壓(齋鬱積夢簾構鹹淵窪鹹) = 憲遞鹹廠積鹽鏇膚膚鑰 鏇蓋簾遞衊夢築艱觸膚 (鬱廠顧築遞窪憲遞餘齋 ) 更多 | 积极 | 2022-06-25 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用